Kolexia
Bidard Francois-Clement Oncologie médicale
Bidard Francois-Clement
Oncologie médicale
Clcc Institut Curie
Paris, France
478 Activités
1.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Cellules tumorales circulantes Métastase tumorale Carcinomes Tumeurs du sein triple-négatives Récidive tumorale locale Carcinome canalaire du sein Adénocarcinome Mélanome

Collaborateurs

Voir plus
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France
Cabel Luc
Cabel Luc
Clcc Institut Curie, Paris, France
Cottu Paul-Henri
Cottu Paul-Henri
Clcc Institut Curie, Paris, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
AstraZeneca
16 collaboration(s)
Dernière en 2023
Novartis
16 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023
Lilly
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
TUC-TOC: Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
Essai Clinique (Seagen)   07 mars 2024
CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial
Essai Clinique (Roche)   01 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
Molecular and clinical portrait of HER2-low invasive lobular carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   28 février 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene   27 février 2024
SUMMIT: An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations
Essai Clinique (Puma Biotechnology)   12 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
TOPOLOGY: A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
Essai Clinique (ProLynx LLC)   07 février 2024